Genetically engineered variant of human tissue plasminogen activator (t-PA), q.v. Derived by deletion of the first kringle domain and the substitution of glutamic acid for arginine at position 275. Prepn: Y. Kawauchi et al., WO 8903874; eidem, US 5556621 (1989, 1996 both to Yamanouchi). Thrombolytic activity: T. Kawasaki et al., Jpn. J. Pharmacol. 63, 9 (1993); M. Suzuki et al., Curr. Ther. Res. 61, 7 (2000). Toxicology: A. Ishikawa et al., J. Toxicol. Sci. 22, 117 (1997). Review of thrombolytic agents: M. Verstraete, Am. J. Med. 109, 52-58 (2000).
Thrombolytic.
Thrombolytic